GRNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GRNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. GreenLight Biosciences Holdings PBC does not have enough data to calculate 10-Year RORE %.
The historical data trend for GreenLight Biosciences Holdings PBC's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GreenLight Biosciences Holdings PBC Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
10-Year RORE % | - | - | - | - |
GreenLight Biosciences Holdings PBC Quarterly Data | ||||||||||||
Dec19 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | |
10-Year RORE % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, GreenLight Biosciences Holdings PBC's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, GreenLight Biosciences Holdings PBC's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where GreenLight Biosciences Holdings PBC's 10-Year RORE % falls into.
GreenLight Biosciences Holdings PBC's 10-Year RORE % for the quarter that ended in Mar. 2023 is calculated as:
10-Year RORE % | = | ( Most Recent EPS (Diluted) | - | First Period EPS (Diluted) ) | / | ( Cumulative EPS (Diluted) for 10-year | - | Cumulative Dividends per Share for 10-year ) |
= | ( | - | ) | / | ( | - | ) | |
= | / | |||||||
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2023 and 10-year before.
GreenLight Biosciences Holdings PBC (NAS:GRNA) 10-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Thank you for viewing the detailed overview of GreenLight Biosciences Holdings PBC's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Deval L Patrick | other: See Remarks | BAIN CAPITAL, LLC, 200 CLARENDON STREET, BOSTON MA 02116 |
Dennis A. Clarke | other: Member of 13D group owning 10% | 6 FERNWAY TERRACE, WINCHESTER MA 01890 |
Cummings Foundation, Inc. | other: Member of 13D group owning 10% | 200 WEST CUMMINGS PARK, WOBURN MA 01801 |
Eric Senior Anderson | other: Member of 13D group owning 10% | 25 N HILL ROAD, WESTOVER MA 01886 |
Mls Capital Fund Ii Lp | other: See remarks | C/O MLSC II (GP) (LABUAN) LLP, ONE MARKET ST SUITE 3525, SAN FRANCISCO CA 94105 |
Chelt Trading Ltd | other: Member of 13D Group | C/O FOX HORAN & CAMERINI LLP, 885 3RD AVENUE, 17TH FLOOR, NEW YORK NY 10022 |
Highview Trust | other: Member of 13D Group | C/O FOX HORAN & CAMERINI LLP, 885 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10022 |
Montealegre Lacayo Jaime Javier | other: Member of 13D Group | APARTADO 15-1250, ESCAZU G2 |
Furneaux Capital Holdco, Llc | other: Member of 13D group | 1 MARINA PARK DRIVE, BOSTON MA 02210 |
Lewis & Clark Plant Sciences Fund I, Lp | other: Member of 13D group | 120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105 |
Lewis & Clark Ventures I, Lp | other: Member of 13D group | 120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105 |
Matthew Allen Walker | director, 10 percent owner | C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155 |
Martha Schlicher | director | C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155 |
Marta Ortega-valle | other: Member of 10% owner group | C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155 |
Builders Vision, Llc | 10 percent owner | 110 NW 2ND STREET SUITE 300, BENTONVILLE AR 72712 |
From GuruFocus
By sperokesalga sperokesalga • 03-30-2023
By PRNewswire PRNewswire • 06-14-2023
By GuruFocusNews GuruFocusNews • 03-14-2022
By GuruFocusNews GuruFocusNews • 06-19-2022
By Business Wire Business Wire • 05-30-2023
By sperokesalga sperokesalga • 05-30-2023
By sperokesalga sperokesalga • 03-01-2023
By GuruFocusNews GuruFocusNews • 02-07-2022
By PRNewswire PRNewswire • 05-30-2023
By GuruFocusNews GuruFocusNews • 05-20-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.